TL;DR: DSIP (delta sleep-inducing peptide) is a naturally occurring nine-amino-acid peptide isolated in 1977 from the brain blood of sleeping rabbits. It has been studied for slow-wave sleep, stress-hormone modulation, and neuroprotection — but its human evidence is old and thin, and its mechanism and receptor remain unidentified.
Delta sleep-inducing peptide, almost always abbreviated DSIP, is one of the oldest and most puzzling molecules in sleep research. It was named for the delta (slow) brain waves that dominate deep, restorative sleep, and for decades it has appeared in discussions of sleep regulation, stress physiology, and cellular protection. Yet nearly fifty years after its discovery, no one has isolated the gene that encodes it or the receptor it acts on. This article explains what DSIP is, what the literature actually shows, and why its evidence base is far weaker than its reputation suggests. It is written strictly for research and educational purposes and is not medical advice.
What is DSIP?
DSIP is a naturally occurring nonapeptide — a chain of nine amino acids — with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (single-letter code WAGGDASGE) and a molecular weight of roughly 849 daltons. It was first characterized in 1977 by Schoenenberger, Monnier and colleagues at the University of Basel through an elegant cross-circulation experiment: cerebral venous blood from rabbits placed into electrically induced sleep was dialyzed and the extract infused into awake recipient rabbits, which then showed enhanced delta-wave EEG activity typical of slow-wave sleep. The factor responsible was purified and named delta sleep-inducing peptide.
A few defining facts about the molecule:
- Structure: A small linear nonapeptide, easily synthesized, with no disulfide bridges
- Origin: Endogenous — DSIP-like immunoreactivity has been detected in mammalian brain, peripheral organs, and plasma
- Naming: Named for a functional observation (delta-sleep induction), not for a known gene or receptor
- Regulatory status: Not an approved drug or supplement in the EU, US, or comparable jurisdictions; distributed only as a research chemical
The crucial caveat is embedded in that history. DSIP was defined by a behavioral effect in one experimental paradigm, not by molecular biology. To this day its precursor protein, encoding gene, and receptor have not been conclusively identified — a highly unusual situation for a peptide that has been studied for decades.
How DSIP is thought to work
There is no settled mechanism of action for DSIP, and honest reviews say so plainly. What exists is a scattered set of pharmacological observations that do not obviously connect into a single pathway.
The most commonly cited ideas include modulation of neurotransmitter systems — DSIP has been reported to interact with glutamatergic (NMDA) and GABAergic signaling, and to trigger calcium-dependent release of met-enkephalin from brainstem tissue. On the endocrine side, DSIP has been described as lowering basal ACTH and cortisol and blunting stress-induced increases, positioning it as a possible modulator of the hypothalamic-pituitary-adrenal (HPA) stress axis rather than a simple sedative. A third strand of work reports antioxidant and neuroprotective effects, including upregulation of antioxidant enzymes and preservation of mitochondrial function under hypoxic or cold stress.
The problem is that none of these observations has been tied to a specific DSIP receptor or a reproducible signaling cascade. In her influential 2006 review, Kovalzon (with Strekalova) went so far as to call DSIP “a still unresolved riddle” and described the sleep-inducing hypothesis itself as poorly documented. Any mechanistic description of DSIP should therefore be read as a collection of hypotheses, not an established model.
What the research shows
The DSIP literature is unusual: it is large in volume but shallow in rigor, and heavily weighted toward older studies and animal models. It helps to separate the evidence by study type.
- 1
1977
Isolated from sleeping-rabbit brain blood; named for delta-wave EEG effect (Schoenenberger & Monnier).
- 2
1980s
Small IV human insomnia studies report better sleep efficiency (Schneider-Helmert) — never robustly replicated.
- 3
2006
Influential review calls DSIP "a still unresolved riddle" (Kovalzon & Strekalova).
- 4
2021
Intranasal DSIP speeds motor recovery in rats after focal stroke (Tukhovskaya et al.).
- 5
2024
BBB-crossing DSIP fusion peptide improves sleep architecture in PCPA insomnia mice (Mu et al.).
Animal studies (the bulk of the data). Most DSIP research is preclinical. The peptide was shown to increase delta and spindle EEG activity in rabbits, rats, and mice, with a more REM-oriented effect reported in cats (Graf and Kastin, 1984). Animal work has also reported stress-axis suppression, anticonvulsant-like effects, and free-radical modulation. More recent rodent studies continue this tradition: a 2021 study reported that intranasal DSIP accelerated motor-function recovery in rats after focal stroke (Tukhovskaya et al.), and a 2024 study reported that a blood-brain-barrier-crossing DSIP fusion peptide improved sleep architecture and rebalanced neurotransmitters in a chemically induced (PCPA) insomnia mouse model (Mu et al.). These are mechanistically interesting but remain animal findings that cannot be assumed to translate to humans.
Human studies (few, old, and mixed). The human evidence is thin. The most-cited positive human work comes from Schneider-Helmert and colleagues in the early-to-mid 1980s, who reported that intravenous synthetic DSIP improved sleep efficiency, reduced nocturnal awakenings, and increased subjective sleep quality in small groups of chronic insomnia patients (Schneider-Helmert, 1986). Critically, these studies were small, single-center, used intravenous administration, and have not been replicated at comparable rigor in the roughly four decades since. Notably, when later investigators applied tighter blinding and controls, the observed sleep effects tended to shrink toward insignificance — a classic warning sign that early enthusiasm outran the data.
The table below summarizes where the different claims actually stand.
| DSIP research claim | Strongest evidence type | Human trial stage | Overall confidence |
|---|---|---|---|
| Increases slow-wave (delta) sleep | Animal EEG + small human studies | Small, dated Phase-equivalent | Low-to-moderate, not replicated |
| Modulates ACTH / cortisol (stress) | Animal models | Not established in humans | Low |
| Antioxidant / neuroprotective | Cell + rodent (e.g. stroke, hypoxia) | None | Preclinical only |
| Defined receptor / mechanism | None conclusive | Not applicable | Very low (unresolved) |
| Corrects circadian / phase-shift sleep | Small human report | Preliminary | Low |
The overall picture: DSIP has a long research history and a genuinely intriguing set of preclinical signals, but the human evidence is scarce, methodologically dated, and not independently confirmed. It should be regarded as a research compound whose headline effect — inducing deep sleep in people — is suggested but not established.
DSIP in context: not a typical “sleep aid”
Because DSIP is discussed alongside sleep and circadian topics, it is often mentally filed next to melatonin or other circadian-oriented peptides. The comparison is imperfect. Melatonin acts through well-characterized MT1/MT2 receptors; DSIP has no identified receptor at all. And unlike compounds framed around resetting circadian rhythm, DSIP’s reported effects span sleep, stress hormones, and cellular protection without a unifying pathway.
It is sometimes contrasted with pineal-linked peptides studied for circadian and longevity endpoints. For readers exploring that adjacent space, our overview of Epithalon, the pineal tetrapeptide covers a mechanistically distinct research area (melatonin-rhythm and telomerase hypotheses) that is likewise dominated by preclinical and small human data. The shared lesson across both is caution: intriguing mechanistic stories are not the same as demonstrated human outcomes.
For laboratory reference details specific to this peptide — including vial fill weights and reconstitution figures — see the DSIP 10mg research profile.
Forms, handling, and reconstitution
In the research supply chain, DSIP is typically distributed as a lyophilized (freeze-dried) powder in sealed vials, commonly at a 5mg or 10mg fill weight. As a short linear peptide with no disulfide bonds, it is generally reconstituted with bacteriostatic water using standard sterile technique before any laboratory use. General handling notes that apply to any small peptide like DSIP:
- Bring vials to room temperature before reconstituting to limit condensation
- Add diluent slowly down the interior wall of the vial rather than directly onto the powder
- Avoid vigorous shaking; a gentle swirl is usually enough to dissolve a nonapeptide
- Confirm the solution is clear and free of visible particulates before use
Because DSIP vials are small and concentrations matter for any measured research work, a reconstitution volume calculation is often the first practical step — our peptide reconstitution calculator handles the concentration math for a given vial size and diluent volume. None of this constitutes dosing guidance for humans; it describes handling of a laboratory reagent only.
Storage and stability
Like most short synthetic peptides, DSIP’s stability depends heavily on temperature, moisture, and light:
- Lyophilized powder: generally stored at approximately -20°C, where it is considered stable for extended periods when kept sealed, dry, and protected from light
- Reconstituted solution: kept refrigerated at 2–8°C and typically used within a few weeks
- General handling: avoid repeated freeze-thaw cycling of reconstituted solution, and minimize light exposure at every stage
Safety, legality, and research disclaimers
DSIP is a research chemical, not an approved pharmaceutical or dietary supplement in the EU, United States, or comparable jurisdictions. It has never completed the large, controlled human trials required for regulatory approval, and comprehensive human safety data — including long-term effects — does not exist. The small historical human studies reported few acute adverse effects, but “no problems reported in a handful of small trials” is not the same as an established safety profile.
Anyone engaging with DSIP should treat it strictly as a laboratory research compound: comply with all applicable local and EU regulations, use it only within appropriate research or institutional settings, and never as a substitute for evaluating and managing sleep problems with a qualified clinician. Nothing here is medical advice, and no information in this article is intended as instructions for human use. For a broader comparison of research peptides and their reference data, the DSIP 10mg profile and related pages provide vial-level details.
Frequently Asked Questions
What is DSIP (delta sleep-inducing peptide)?
DSIP is a naturally occurring nine-amino-acid peptide (sequence WAGGDASGE) first isolated in 1977 from the cerebral blood of sleeping rabbits. It is named for the delta brain waves of deep sleep and is studied in research settings for slow-wave sleep, stress-hormone modulation, and neuroprotection.
Does DSIP actually work for sleep in humans?
The evidence is limited and dated. Small studies from the 1980s reported improved sleep efficiency in chronic insomnia patients, but they were tiny, single-center, used intravenous administration, and have not been robustly replicated. More rigorous testing tended to show weaker effects, so human efficacy remains unproven rather than confirmed.
How does DSIP work mechanistically?
Honestly, no one is certain. DSIP has been linked to NMDA and GABA signaling, met-enkephalin release, and suppression of the ACTH-cortisol stress axis, but no specific DSIP receptor, precursor protein, or gene has been conclusively identified. A widely cited 2006 review described DSIP as “a still unresolved riddle.”
Is DSIP the same as melatonin or a normal sleep aid?
No. Melatonin acts through well-defined MT1/MT2 receptors and is an approved supplement in many regions, whereas DSIP has no identified receptor and is only a research chemical. DSIP’s reported effects also extend beyond sleep to stress hormones and cellular protection, without a single unifying mechanism.
Is DSIP legal and approved?
DSIP is not approved as a medicine or supplement in the EU, US, or comparable jurisdictions and is generally handled only as a research chemical, not authorized for human consumption. Legal status can vary by country, so always confirm current local and institutional regulations before any research use.
Why is DSIP still considered mysterious after almost 50 years?
Because it was defined by a behavioral effect rather than by molecular biology. Despite decades of study, its gene, precursor, and receptor have never been isolated, and its many reported effects (sleep, stress, antioxidant activity) do not connect through a known pathway — leaving both mechanism and clinical relevance unresolved.
References
- Schoenenberger GA, Monnier M. “Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.” Proceedings of the National Academy of Sciences USA. 1977;74(3):1282-1286.
- Graf MV, Kastin AJ. “Delta-sleep-inducing peptide (DSIP): a review.” Neuroscience and Biobehavioral Reviews. 1984;8(1):83-93.
- Graf MV, Kastin AJ. “Delta-sleep-inducing peptide (DSIP): an update.” Peptides. 1986;7(6):1165-1187.
- Schneider-Helmert D. “DSIP in sleep disturbances.” European Neurology. 1986;25(Suppl 2):154-157.
- Kovalzon VM, Strekalova TV. “Delta sleep-inducing peptide (DSIP): a still unresolved riddle.” Journal of Neurochemistry. 2006;97(2):303-309.
- Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. “Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.” Molecules. 2021;26(17):5173.
- Mu X, Qu L, Yin L, Wang L, Liu X, Liu D. “Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.” Frontiers in Pharmacology. 2024;15:1439536.
Last updated: July 7, 2026
Disclaimer: This information is for educational and research purposes only. DSIP is a research chemical, not an approved medicine or supplement, and is not intended for human consumption. This is not medical advice.